secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102433
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent reports positive SUMMIT trial, Q2 net loss $73.5M; pro-forma cash $453M
------------------------------------------------------------------------------

- SUMMIT trial met primary endpoint: TSS improvement 8.91 points vs placebo (p=0.0002); 87.4% bezuclastinib patients had ≥50% tryptase reduction.
- Upcoming milestones: PEAK and APEX top-line results in 2H 2025; NDA submission by end of 2025.
- Q2 net loss $73.5M (vs $59.0M YoY); R&D $62.2M; G&A $13.4M; cash $237.8M at June 30, 2025.
- Pro-forma cash $453M including $215.8M net from July upsized offering; $400M debt facility with SLR Capital.
- Inducement grants to 6 new employees: 172,450 options at $9.00, 10-yr term, 4-yr vest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/0000950170-25-102433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer